Log in using OpenID

Rivastigmine Market Pegged to Expand Robustly By 2026

Increasing Prevalence Of Cardiovascular Diseases Worldwide Also Accounts For The Development Of Alzheimer’s Disease, Thereby Boosting Demand For Rivastigmine.
Rivastigmine Market Size, Share, Trend,
Outlook, Future Analysis And Synthesis By
Rivastigmine is a cholinesterase enzyme inhibitor, which acts on butylcholinesterase and
acetylcholinesterase. It is a cholinergic agent that aids in the treatment of Alzheimer’s and Parkinson’s
disease. The drug can be administered orally or in transdermal patches form, owing to its small
molecular size.
Rivastigmine Market – Dynamics
Increasing geriatric population is a major driver for growth of the rivastigmine market. According to The
Alzheimer Association, in 2018, the risk of suffering from dementia can increase double fold above the
age of 65 years in every 5 years. Moreover, increasing prevalence of cardiovascular diseases worldwide
also accounts for the development of Alzheimer’s disease, thereby boosting demand for rivastigmine. As
per the National Center for Biotechnology Information published in 2013, the incidence of cardiovascular
diseases was around 22.5 per 1,000 person worldwide which in turn suggesting a risk of
dementia.Diseases such as diabetes and blood pressure can also increase the risk of dementia, which
further boosts demand for rivastigmine, thereby propelling the market growth.
Request For Sample Copy of Research @
Rivastigmine Market – Regional Insights
The rivastigmine market is segregated geographically into North America, Latin America, Asia
Pacific, Europe, Middle East, and Africa. North America accounted for the largest share in the
global rivastigmine market in 2017. This is owing to increasing prevalence of chronic kidney
disease in the region that may lead to dementia. According to The American Kidney Fund,
around 31 million people suffered from chronic kidney disease in 2015. Europe accounted for
the second largest share in terms of revenue in the global rivastigmine market, in 2017 owing
to increasing geriatric population in the region. Geriatric population is more prone to dementia.
According to World Population Prospects (WPP), in 2017, around 25% of the population in
Europe was aged 60 years or above. According to the Alzheimer’s Association, in 2017, there
was significant prevalence of vascular diseases in Latin America and Africa. Therefore, Latin
America and Africa are expected to witness significant growth in the global rivastigmine market
during the forecast period.
Report includes chapters which deeply display the following deliverable about industry :
• Rivastigmine Market Research Objective and Assumption
• Rivastigmine Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Rivastigmine Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Rivastigmine Market, By Regions
• Rivastigmine Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Rivastigmine Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Rivastigmine Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Research Findings and Conclusion
Rivastigmine Market – Competitive Landscape
Major players operating in the global rivastigmine market include, Novartis Europharm Limited, Actavis
Pharma, Apotex Corporation, Aurobindo Pharm Ltd, Teva Pharmaceuticals Industries Ltd, Dr. Reddy’s
Laboratories, Macleods, and others. Key players in the market are focused on product development and
approvals in order to enhance their market share. For instance, in 2007, U.S. FDA approved Exelon
(Rivastigmine tartarate) — developed by Novartis Europharm Limited for the treatment of Alzheimer's
and Parkinson's disease.
Global Rivastigmine Market Taxonomy:
On the basis of disease indication, the global rivastigmine market is segmented into:
Alzheimer’s disease
Parkinson’s disease
On the basis of formulation, the global rivastigmine market is segmented into:
Transdermal Patches
Browse Complete Research Report @
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Poul Master
Poul Master247   documents Email
Health and Medicine
File Size
106 KB
Rivastigmine Market, rivastigmine
Report inappropriate content